Asiatic acid (Synonyms: 积雪草酸)

目录号: HY-N0194 纯度: 99.40%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Asiatic acid，是在积雪草 (Centella asiatica) 中发现的一种五环三萜，具有抗癌活性。Asiatic acid 可诱导黑色素瘤细胞凋亡 (apoptosis)，并对人主动脉内皮细胞（HAEC）具有屏障保护作用。Asiatic acid 还具有抗炎活性，可抑制肿瘤坏死因子 (TNF)-α 诱导的内皮屏障功能障碍。Asiatic acid 还抑制 NLRP3 炎症小体激活和 NF-κB 通路，有效抑制大鼠炎症，并在大鼠脊髓损伤 (SCI) 模型中具有神经保护作用。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Asiatic acid Chemical Structure

CAS No. : 464-92-6

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥172	In-stock
5 mg	￥160	In-stock
10 mg	￥250	In-stock
25 mg	￥366	In-stock
50 mg	￥500	In-stock
100 mg	￥750	In-stock
500 mg	￥1863	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Asiatic acid:

Asiatic acid (Standard) 询价

MCE 顾客使用本产品发表的 3 篇科研文献

Asiatic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Parasite 亚型特异性产品:

查看所有亚型

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

生物活性
纯度 & 产品资料
参考文献

生物活性

Asiatic acid, a pentacyclic triterpene found in Centella asiatica (Centella asiatica), has anticancer activity. Asiatic acid induces apoptosis in melanoma cells and has barrier protective effects on human aortic endothelial cells (HAEC). Asiatic acid also has anti-inflammatory activity and inhibits tumor necrosis factor (TNF)-α-induced endothelial barrier dysfunction. Asiatic acid also inhibits NLRP3 inflammasome activation and NF-κB pathway, effectively inhibits inflammation in rats, and has neuroprotective effects in rat spinal cord injury (SCI) model^[1]^[2]^[3]^[4]^[5].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
518A2	EC₅₀	21.9 μM Compound: AA	Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
8505C	EC₅₀	16.8 μM Compound: AA	Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
A2780	EC₅₀	28.2 μM Compound: AA	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
A-375	IC₅₀	50.33 μM Compound: AA; Asiatic Acid	Cytotoxicity against human A375 cells after 72 hrs by MTT assay Cytotoxicity against human A375 cells after 72 hrs by MTT assay	[PMID: 26974379]
A549	IC₅₀	> 100 μM Compound: AA	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
A549	IC₅₀	> 20 μM Compound: AA	Inhibition of NFkappaB (unknown origin) expressed in human A549 cells co-transfected with pNFkappaB-Luc vector assessed as reduction in TNFalpha-induced NFkappaB transcriptional activity co-incubated for 7 hrs in presence of TNFalpha by bright-glo lucifer Inhibition of NFkappaB (unknown origin) expressed in human A549 cells co-transfected with pNFkappaB-Luc vector assessed as reduction in TNFalpha-induced NFkappaB transcriptional activity co-incubated for 7 hrs in presence of TNFalpha by bright-glo lucifer	[PMID: 31057738]
A549	IC₅₀	18.8 μM Compound: AA 6	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 28754470]
A549	EC₅₀	26.2 μM Compound: AA	Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
A549	IC₅₀	37.81 μM Compound: AA 6	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 28754470]
A549	IC₅₀	41.02 μM Compound: AA	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 31057738]
BJ	IC₅₀	88.7 μM Compound: AA; Asiatic Acid	Cytotoxicity against human BJ cells after 72 hrs by MTT assay Cytotoxicity against human BJ cells after 72 hrs by MTT assay	[PMID: 26974379]
CHO	EC₅₀	> 10 μM Compound: Asiatic acid	Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay	[PMID: 19911773]
COS-1	EC₅₀	0 μM Compound: Asiatic acid	Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay	[PMID: 19911773]
Epithelial cell	IC₅₀	> 20 μM Compound: asiatic acid	Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay	[PMID: 18826277]
H9	IC₅₀	9 μg/mL Compound: 8	Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA	[PMID: 9748372]
HeLa	IC₅₀	37.26 μM Compound: AA	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25151580]
HeLa	IC₅₀	4 μM Compound: AA 6	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 28754470]
HeLa	IC₅₀	52.47 μM Compound: AA 6	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28754470]
HeLa	IC₅₀	52.47 μM Compound: AA; Asiatic Acid	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 26974379]
HeLa	IC₅₀	91.07 μM Compound: AA	Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
HepG2	IC₅₀	> 10 μM Compound: 24	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27797185]
HepG2	IC₅₀	34.9 μM Compound: AA	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25151580]
HepG2	IC₅₀	35.37 μM Compound: AA	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 31057738]
HT-29	EC₅₀	> 30 μM Compound: AA	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
HT-29	IC₅₀	64.3 μM Compound: AA; Asiatic Acid	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 26974379]
HT-29	IC₅₀	64.33 μM Compound: AA 6	Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28754470]
HUVEC	IC₅₀	> 100 μM Compound: AA 6	Cytotoxicity in HUVEC cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in HUVEC cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 28754470]
HUVEC	IC₅₀	> 100 μM Compound: AA	Cytotoxicity against human HUVEC cells after 48 hrs by MTT assay Cytotoxicity against human HUVEC cells after 48 hrs by MTT assay	[PMID: 25151580]
Jurkat	IC₅₀	37.17 μM Compound: AA; Asiatic Acid	Cytotoxicity against human Jurkat cells after 72 hrs by XTT assay Cytotoxicity against human Jurkat cells after 72 hrs by XTT assay	[PMID: 26974379]
L02	IC₅₀	> 50 μM Compound: AA	Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay	[PMID: 31057738]
MCF7	IC₅₀	> 10 μM Compound: 24	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27797185]
MCF7	EC₅₀	> 30 μM Compound: AA	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
MCF7	GI₅₀	19.1 μM Compound: AA 6	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 28754470]
MCF7	IC₅₀	32.8 μM Compound: AA 6	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 28754470]
MCF7	IC₅₀	67.58 μM Compound: AA	Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
MCF7	IC₅₀	68.5 μM Compound: AA; Asiatic Acid	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26974379]
MDA-MB-231	GI₅₀	18.1 μM Compound: AA 6	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 28754470]
MGC-803	IC₅₀	22.57 μM Compound: AA	Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 25151580]
MIA PaCa-2	IC₅₀	50.67 μM Compound: AA; Asiatic Acid	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay	[PMID: 26974379]
NCI-H460	IC₅₀	39.55 μM Compound: AA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 25151580]
NCI-H460	IC₅₀	44.82 μM Compound: AA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 31057738]
NCI-N87	IC₅₀	> 10 μM Compound: 24	Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay	[PMID: 27797185]
NIH3T3	EC₅₀	26.2 μM Compound: AA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
PC-3	IC₅₀	53.6 μM Compound: AA 6	Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 28754470]
PC-3	IC₅₀	67.25 μM Compound: AA; Asiatic Acid	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 26974379]
RAW264.7	IC₅₀	74.8 μM Compound: 4	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs	[PMID: 21353543]
RAW264.7	IC₅₀	8.6 μM Compound: 4	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 21353543]
Sf21	IC₅₀	> 40 μM Compound: 25	Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	[PMID: 31774676]
SGC-7901	IC₅₀	36.8 μM Compound: AA 6	Cytotoxicity in human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity in human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 28754470]
T-24	IC₅₀	33.72 μM Compound: AA 6	Cytotoxicity in human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 28754470]
T-24	IC₅₀	43.97 μM Compound: AA	Cytotoxicity against human T24 cells after 48 hrs by MTT assay Cytotoxicity against human T24 cells after 48 hrs by MTT assay	[PMID: 31057738]

体外研究
(In Vitro)

Asiatic acid 通过维持粘附连接 (AJ) 并抑制紧密连接 (TJ) 重新分布，来产生屏障稳定作用而抵抗 TNF-α^[2]。
Asiatic acid (40 μM) 可稳定细胞外周的 F-肌动蛋白和二磷酸-MLC，并阻止它们受 TNF-α (10 ng/mL; 1 h) 刺激的重排。但 Asiatic acid (10-30 μM; 6 h) 不能减少F-肌动蛋白的聚集^[2]。
Asiatic acid (40 μM; 6 h) 保留细胞与细胞接触区域的网状结构，消除了 TNF-α 诱导的血管内皮 (VE)-钙粘蛋白和 β-连环蛋白的结构重组^[2]。
但 Asiatic acid (10-40 μM; 6 h) 对 cytochalasin D (5 μM; 15 min) 增加的内皮细胞通透性没有抑制作用。Asiatic acid 增加肌球蛋白轻链 (MLC) 的二磷酸化^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Asiatic acid (5-75 mg/kg; 胃内强饲; 每天 1 次) 在病原体诱导大鼠疾病模型中，有效抑制了大鼠的盆腔炎 (PID)，发挥抗氧化和抗炎作用^[3]。
Asiatic acid (30 mg/kg, 75 mg/kg; 胃内注射, 每天 1 次) 通过抑制炎症和氧化应激，对大鼠脊髓损伤 (SCI) 具有神经保护作用^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

488.70

Formula

C₃₀H₄₈O₅

CAS 号

464-92-6

性状

固体

颜色

White to off-white

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 250 mg/mL (511.56 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0462 mL	10.2312 mL	20.4625 mL
5 mM	0.4092 mL	2.0462 mL	4.0925 mL
10 mM	0.2046 mL	1.0231 mL	2.0462 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.25 mg/mL (4.60 mM); 澄清溶液

此方案可获得 ≥ 2.25 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 22.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (4.26 mM); 悬浊液; 超声助溶

此方案可获得 2.08 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (4.26 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.40%

选择批次：

Data Sheet (653 KB) SDS (393 KB)

COA (197 KB) LCMS (257 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Park BC, et al. Asiatic acid induces apoptosis in SK-MEL-2 human melanoma cells. Cancer Lett. 2005 Jan 31;218(1):81-90. [Content Brief]

[2]. Huang SS, et al. Antinociceptive activities and the mechanisms of anti-inflammation of asiatic Acid in mice. Evid Based Complement Alternat Med. 2011;2011:895857. [Content Brief]

[3]. Fong LY, et al. Asiatic acid stabilizes cytoskeletal proteins and prevents TNF-α-induced disorganization of cell-cell junctions in human aortic endothelial cells. Vascul Pharmacol. 2019 Jun;117:15-26. [Content Brief]

[4]. Jiang W, et al. Neuroprotective effect of asiatic acid against spinal cord injury in rats. Life Sci. 2016 Jul 15;157:45-51. [Content Brief]

[5]. Kong D, et al. Protective effects of Asiatic acid against pelvic inflammatory disease in rats. Exp Ther Med. 2019 Jun;17(6):4687-4692. [Content Brief]

Asiatic acid 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.0462 mL	10.2312 mL	20.4625 mL	51.1561 mL
	5 mM	0.4092 mL	2.0462 mL	4.0925 mL	10.2312 mL
	10 mM	0.2046 mL	1.0231 mL	2.0462 mL	5.1156 mL
	15 mM	0.1364 mL	0.6821 mL	1.3642 mL	3.4104 mL
	20 mM	0.1023 mL	0.5116 mL	1.0231 mL	2.5578 mL
	25 mM	0.0818 mL	0.4092 mL	0.8185 mL	2.0462 mL
	30 mM	0.0682 mL	0.3410 mL	0.6821 mL	1.7052 mL
	40 mM	0.0512 mL	0.2558 mL	0.5116 mL	1.2789 mL
	50 mM	0.0409 mL	0.2046 mL	0.4092 mL	1.0231 mL
	60 mM	0.0341 mL	0.1705 mL	0.3410 mL	0.8526 mL
	80 mM	0.0256 mL	0.1279 mL	0.2558 mL	0.6395 mL
	100 mM	0.0205 mL	0.1023 mL	0.2046 mL	0.5116 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Asiatic acid464-92-6ApoptosisParasiteActinAnti-hyperpermeabilityDiphosphorylated myosin light chainEndothelial cell-cell junctionsHuman aortic endothelial cellsTNF-αinflammatory responsenuclear factor-κBnucleotide-binding domain-like receptor protein 3 inflammasomepelvic inflammatory diseaseInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Asiatic acid (Synonyms: 积雪草酸)

Customer Review

Other Forms of Asiatic acid:

MCE 顾客使用本产品发表的 3 篇科研文献

Asiatic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Parasite 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Asiatic acid 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Asiatic acid (Synonyms: 积雪草酸)

Customer Review

Other Forms of Asiatic acid:

Asiatic acid 相关抗体

MCE 顾客使用本产品发表的 3 篇科研文献

Asiatic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Parasite 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Asiatic acid 相关抗体:

摩尔计算器

稀释计算器

Asiatic acid 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z